Jeil Pharmaceutical Co.,Ltd
KRX:271980.KS
15180 (KRW) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 726,393.758 | 722,229.924 | 700,693.229 | 691,324.837 | 671,406.875 | 627,074.758 | 371,591.763 | 617,279.88 | 594,715.655 |
| Cost of Revenue
| 542,579.096 | 565,431.766 | 544,716.84 | 534,633.671 | 519,483.226 | 488,442.689 | 294,552.495 | 483,523.029 | 456,032.632 |
| Gross Profit
| 183,814.662 | 156,798.159 | 155,976.389 | 156,691.166 | 151,923.649 | 138,632.069 | 77,039.267 | 133,756.85 | 138,683.023 |
| Gross Profit Ratio
| 0.253 | 0.217 | 0.223 | 0.227 | 0.226 | 0.221 | 0.207 | 0.217 | 0.233 |
| Reseach & Development Expenses
| 45,727.389 | 41,147.44 | 38,973.748 | 24,270.197 | 22,113.876 | 24,875.652 | 13,505.304 | 21,835.104 | 19,677.625 |
| General & Administrative Expenses
| 33,503.112 | 30,767.008 | 25,353.195 | 22,385.062 | 25,154.707 | 19,258.726 | 11,675.166 | 0 | 0 |
| Selling & Marketing Expenses
| 42,978.445 | 43,865.758 | 49,370.856 | 48,001.053 | 46,003.055 | 38,520.859 | 18,494.342 | 0 | 0 |
| SG&A
| 128,687.497 | 74,632.766 | 74,724.051 | 70,386.115 | 71,157.762 | 57,779.585 | 30,169.508 | 102,568.585 | 105,856.964 |
| Other Expenses
| -511.828 | 54,350.146 | 52,658.495 | 49,130.481 | 58,276.901 | 696.778 | 82.074 | 0 | 0 |
| Operating Expenses
| 174,926.714 | 170,130.352 | 166,356.294 | 143,786.793 | 151,548.539 | 131,241.995 | 72,073.182 | 124,403.689 | 125,534.589 |
| Operating Income
| 8,887.949 | -13,332.193 | -5,635.668 | 12,904.373 | 1,058.981 | 7,390.074 | 4,966.085 | 9,353.161 | 13,148.434 |
| Operating Income Ratio
| 0.012 | -0.018 | -0.008 | 0.019 | 0.002 | 0.012 | 0.013 | 0.015 | 0.022 |
| Total Other Income Expenses Net
| -7,786.96 | 85.548 | -8,198.303 | -352.383 | -1,999.838 | -2,501.626 | -1,642.801 | 4,449.224 | 2,901.228 |
| Income Before Tax
| 1,100.989 | -13,246.645 | -13,833.971 | 12,551.99 | -940.857 | 4,888.448 | 3,323.284 | 13,802.385 | 16,049.662 |
| Income Before Tax Ratio
| 0.002 | -0.018 | -0.02 | 0.018 | -0.001 | 0.008 | 0.009 | 0.022 | 0.027 |
| Income Tax Expense
| -3,284.477 | 1,762.368 | 1,151.646 | 5,587.188 | 9,643.736 | 2,999.415 | 2,255.69 | 5,912.13 | 6,288.291 |
| Net Income
| 5,004.745 | -15,009.014 | -14,985.618 | 6,916.121 | -10,584.593 | 1,889.033 | 1,067.595 | 7,890.255 | 9,761.371 |
| Net Income Ratio
| 0.007 | -0.021 | -0.021 | 0.01 | -0.016 | 0.003 | 0.003 | 0.013 | 0.016 |
| EPS
| 343.46 | -1,029.79 | -1,025.79 | 473.24 | -721.28 | 142 | 72.86 | 442.51 | 547.45 |
| EPS Diluted
| 343.46 | -1,029.79 | -1,025.79 | 473.24 | -721.28 | 142 | 72.86 | 442.51 | 547.45 |
| EBITDA
| 18,655.049 | -4,713.271 | 3,496.934 | 23,111.005 | 8,664.949 | 13,019.753 | 8,224.238 | 17,033.498 | 21,613.091 |
| EBITDA Ratio
| 0.026 | -0.007 | 0.005 | 0.033 | 0.013 | 0.021 | 0.022 | 0.028 | 0.036 |